Arcutis Biotherapeutics, a biopharmaceutical company, has filed an amended quarterly report for the period ending March 31, 2024. The amendment, submitted to the SEC, includes the addition of a Rule 10b5-1 trading plan by board member Howard G. Welgus, M.D., which was previously omitted. The plan allows for the potential sale of up to 93,386 shares of common stock and the exercise and sale of up to 26,614 options between June 4, 2024, and May 30, 2025. This filing also includes new certifications by the company's principal executive officer and principal financial officer as required by the SEC. No financial statements were included in this amendment, and it does not reflect any events post the original filing date. The company's common stock is registered on The...Show More

Arcutis Biotherapeutics, a biopharmaceutical company, has filed an amended quarterly report for the period ending March 31, 2024. The amendment, submitted to the SEC, includes the addition of a Rule 10b5-1 trading plan by board member Howard G. Welgus, M.D., which was previously omitted. The plan allows for the potential sale of up to 93,386 shares of common stock and the exercise and sale of up to 26,614 options between June 4, 2024, and May 30, 2025. This filing also includes new certifications by the company's principal executive officer and principal financial officer as required by the SEC. No financial statements were included in this amendment, and it does not reflect any events post the original filing date. The company's common stock is registered on The Nasdaq Global Select Market under the symbol ARQT. As of May 10, 2024, the number of outstanding shares was reported to be 115,764,164. The company's business developments include amended agreements with Cowen and Company, LLC, and employment agreements, as well as licensing agreements with Sato Pharmaceutical Co., Ltd., and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. The future plans or strategic initiatives of Arcutis Biotherapeutics were not disclosed in this amendment.